聚氧乙烯氢化蓖麻油结构式
|
常用名 | 聚氧乙烯氢化蓖麻油 | 英文名 | Ethoxylated hydrogenated castor oil |
---|---|---|---|---|
CAS号 | 61788-85-0 | 分子量 | 375.864 | |
密度 | 1.2±0.1 g/cm3 | 沸点 | 529.0±50.0 °C at 760 mmHg | |
分子式 | C21H23ClFNO2 | 熔点 | N/A | |
MSDS | 美版 | 闪点 | 273.8±30.1 °C |
聚氧乙烯氢化蓖麻油用途Ethoxylated hydrogenated castor oil (PEG-40 hydrogenated castor oil) 是聚乙二醇 (PEG) 与天然蓖麻油的混合物。Ethoxylated hydrogenated castor oil 可用于水包油 (o/w) 乳浊液的乳化和增溶。Ethoxylated hydrogenated castor oil 可以作为动物实验的助溶剂。 |
中文名 | 聚氧乙烯氢化蓖麻油 |
---|---|
英文名 | Ethoxylated hydrogenated castor oil |
中文别名 | 氟哌啶醇 |
英文别名 | 更多 |
描述 | Ethoxylated hydrogenated castor oil (PEG-40 hydrogenated castor oil) 是聚乙二醇 (PEG) 与天然蓖麻油的混合物。Ethoxylated hydrogenated castor oil 可用于水包油 (o/w) 乳浊液的乳化和增溶。Ethoxylated hydrogenated castor oil 可以作为动物实验的助溶剂。 |
---|---|
相关类别 | |
体内研究 | 20%PEG-40氢化蓖麻油(10μl) 应用于鼠标左耳,右耳作为控件。观察6天小鼠胸腺发育情况,未观察到刺激迹象[1]。PEG-40氢化蓖麻油(尾静脉注射;300、900和2700毫克/千克;4周)用于短期毒性。PEG-40氢化蓖麻油在300和900 mg/kg剂量下无全身毒性。然而,在2700 mg/kg的剂量下,观察到轻微的共济失调,男性体重显著降低,女性体重略有降低[1]。以PEG-40氢化蓖麻油为表面活性剂,对空白纳米乳液进行了毒性研究,以负载多种活性化合物进行口服给药[2]。用近20%的PEG-40氢化蓖麻油将单油酸甘油酯(GMO)作为油乳化到水相中。在Webster小鼠中,给小鼠口服5000mg/kg空白纳米乳剂,每天一次,持续14天,这种纳米乳剂不会产生有害影响,并且对食物摄入没有影响[2]。 |
参考文献 |
密度 | 1.2±0.1 g/cm3 |
---|---|
沸点 | 529.0±50.0 °C at 760 mmHg |
分子式 | C21H23ClFNO2 |
分子量 | 375.864 |
闪点 | 273.8±30.1 °C |
精确质量 | 375.140137 |
LogP | 3.01 |
外观性状 | 淡黄色油状糊状 |
蒸汽压 | 0.0±1.5 mmHg at 25°C |
折射率 | 1.581 |
储存条件 | 塑料袋或牛皮纸外套编织袋包装。贮存于阴凉、干燥通风的库房中。 |
稳定性 | 远离氧化物,阳光,热,明火,高温,火花,静电电荷,其他点火源。 |
更多 | 1. 性状:为白青色细粉。 2. 密度(g/mL,25/4℃):1.02 3. 相对蒸汽密度(g/mL,空气=1):未确定 4. 熔点(ºC):未确定 5. 沸点(ºC,常压):未确定 6. 沸点(ºC,5.2kPa):未确定 7. 折射率:未确定 8. 闪点(ºC):288 9. 比旋光度(º):未确定 10. 自燃点或引燃温度(ºC):未确定 11. 蒸气压(kPa,25ºC):未确定 12. 饱和蒸气压(kPa,60ºC):未确定 13. 燃烧热(KJ/mol):未确定 14. 临界温度(ºC):未确定 15. 临界压力(KPa):未确定 16. 油水(辛醇/水)分配系数的对数值:未确定 17. 爆炸上限(%,V/V):未确定 18. 爆炸下限(%,V/V):未确定 19. 溶解性:不溶于水。 |
危险品运输编码 | NONH for all modes of transport |
---|
Formulation and biopharmaceutical evaluation of silymarin using SMEDDS.
Arch. Pharm. Res. 30(1) , 82-9, (2007) Silymarin has been used to treat hepatobiliary diseases. However, it has a low bioavailability after being administered orally on account of its low solubility in water. In order to improve the dissol... |
|
Preparation and evaluation of self-nanoemulsifying tablets of carvedilol.
AAPS PharmSciTech 10(1) , 183-92, (2009) The purpose of this study was to combine the advantages of self-nanoemulsifying drug delivery systems and tablets as a conventional dosage form emphasizing the excipients' effect on the development of... |
|
Detailed molecular characterization of castor oil ethoxylates by liquid chromatography multistage mass spectrometry.
J. Chromatogr. A. 1218(40) , 7166-72, (2011) The molecular characterization of castor oil ethoxylates (CASEOs) was studied by reverse-phase liquid chromatography (RPLC) mass spectrometry (MS) and multistage mass spectrometry (MS(n)). The develop... |
Brotopon |
Einalon S |
Eukystol |
4-[4-(4-Chlorophenyl)-4-hydroxy-1-piperidinyl]-1-(4-fluorophenyl)-1-butanone |
Peluces |
Haldol |
Halosten |
Linton |
Aloperidin |
4-[4-(p-Chlorophenyl)-4-hydroxypiperidino]-4'-fluorobutyrophenone |
Sigaperidol |
Butyrophenone, 4-[4- (p-chlorophenyl)-4-hydroxypiperidino]-4'-fluoro- |
haloperidol |
Haloperidol [USAN:BAN:INN:JAN] |
1-Butanone, 4-[4- (4-chlorophenyl)-4-hydroxy-1-piperidinyl]-1-(4-fluorophenyl)- |
1-Butanone, 4-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-1-(4-fluorophenyl)- |
4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-1-(4-fluorophenyl)butan-1-one |
Serenace |
4-[4-(4-Chlorphenyl)-4-hydroxypiperidin-1-yl]-1-(4-fluorphenyl)butan-1-on |
Bioperidolo |
Dozic |
Keselan |